Released Mar 18, 2026, before the open
10-K filed Mar 18, 2026, 77 days after period end · 0001104659-26-029858
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$9.12M$9.12M derived−49.9% vs Q4 2024−48.9% vs Q3 2025
Net Income-$5.50M-$5.50M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$4,658,000N/M
Operating Cash Flowderived$2,030,000−49.1%
Free Cash Flowderived$1,627,000−54.4%
Margins · derived
Operating margin-51.1%−90.6 pt vs Q4 2024
Net margin-60.3%−96.0 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $9.12M | $18.22M | $10.49M | $8.62M |
| Net Income | -$5.50M | $6.49M | -$6.04M | -$3.74M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR